LLSC Corporate News

News

Read all The Leukemia & Lymphoma Society of Canada's press releases

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday.

 
Regina Kulikowski
Director Health Communications and Stakeholder Engagement

 

News Releases

LLSC Chair Receives Award for Exemplary Leadership & Raising Over $1 Million

Gilles Legault, CN’s Senior Counsel, Global Legal Affairs, recipient of 2016 distinguished Dr.  Kenneth B. McCredie Award FOR IMMEDIATE RELEASE July 11, 2016, Toronto  — The Leukemia & Lymphoma Society of Canada is pleased to announce that Gilles Legault, current chair of LLSC, has been awarded the prestigious Dr. Kenneth McCredie award. The award is being conferred as p...

LLSC Garners Support of Prominent Business Leaders

FOR IMMEDIATE RELEASE June 2, 2016, Toronto — The Leukemia & Lymphoma Society of Canada, Ontario Region, is pleased to announce that Mark Barrenechea, CEO of OpenText Corp., and Ted Moroz, President of the Beer Store, have pledged their support to the Light The Night Walk signature fundraising event. “We are excited that prominent business leaders Ted Moroz and Mark Barrenechea together with their staff...

Light the Night to Help End Blood Cancers

February 4, 2016, Toronto — Starting on World Cancer Day, Feb. 4, the Leukemia & Lymphoma Society of Canada invites all Canadians to post a light on its virtual map to join the fight against blood cancers. The campaign kicks off registration for our annual Light The Night Walks. “We want to show the more than 110,000 Canadians affected by blood cancers that they have the support of the entire country,” s...

The Leukemia & Lymphoma Society Announces Progress Against Devastating Disease

For Immediate Release
Contact: Andrea Greif
Tel: (914) 821-8958
Cell: (914) 772-3027
andrea.greif@lls.org   NEWS RELEASE The Leukemia & Lymphoma Society Announces Progress Against Devastating Disease LLS-Funded Investigational Therapy for High-Risk Acute Myeloid Leukemia Patients Significantly Outperforms Standard Therapy in Phase 3 Clinical Trial White Plains, N.Y....

Pages